<DOC>
	<DOCNO>NCT01849562</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability efficacy 12 week treatment sovaprevir , ACH-0143102 ribavirin GT1 , treatment-naive , HCV subject .</brief_summary>
	<brief_title>Safety , Tolerability Efficacy 12-weeks Sovaprevir , ACH-3102 Ribavirin Treatment-naive GT-1 HCV Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>Males Females age 18 65 Chronic HCV infection HCV genotype 1 HCV RNA &gt; 10,000 IU/mL screening . Female patient must willing use two effective method contraception , one must barrier method , dose period six month last dose ribavirin . Females childbearing potential must negative pregnancy test screen baseline . Male patient must willing use effective barrier method contraception throughout dose period six month . Signed date write informed consent form . Willing participate study activity study requirement ( include effective contraception ) study period . Treatment na√Øve subject define subject never receive pegylated interferon , RBV , directacting antiviral agent treatment chronic HCV infection . A liver biopsy within last 3 year without evidence cirrhosis . Body Mass Index ( BMI ) &gt; 36.0 Pregnant nursing ( lactate ) female , confirm positive human chorionic gonadotropin ( HCG ) laboratory test female contemplate pregnancy Participation interventional clinical trial within 35 day prior first study medication dose administration Day 1 Known HIV1 HIV2 infection/serology and/or positive Hepatitis B Surface Antigen ( HBsAg ) Use dietary supplement , grapefruit juice , herbal supplement , CYP2C8 substrates , CYP3A4 inducers inhibitor , PGP inducer substrate , OATP inhibitor substrates , potent inducer CYP enzymes within 14 day prior dose 7 day follow completion study med . Clinically significant laboratory abnormality screening ( specify protocol ) Other form liver disease History severe uncontrolled psychiatric disease History malignancy organ system , treat untreated within past 5 year History major organ transplantation Use bone marrow colony stimulate factor agent within 3 month prior baseline . History seizure disorder require ongoing medical therapy History know coagulopathy include hemophilia History hemoglobinopathy , include sickle cell anemia thalassemia . History immunologically mediate disease ( specify protocol ) History clinical evidence significant chronic cardiac disease ( specify protocol ) ECG clinically significant abnormality . Structural functional cardiac abnormality ( specify protocol ) History COPD , emphysema , chronic lung disease . Subjects currently abuse amphetamine , cocaine opiate , ongoing alcohol abuse judgement investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Hepatitis C , Chronic</keyword>
	<keyword>Genotype 1</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Liver Diseases</keyword>
	<keyword>Hepatitis , viral , human</keyword>
	<keyword>ribavirin</keyword>
	<keyword>antiviral agent</keyword>
	<keyword>anti-infective agent</keyword>
	<keyword>protease inhibitor</keyword>
	<keyword>NS5a inhibitor</keyword>
</DOC>